| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/08/2001 | WO2001009121A2 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 02/08/2001 | WO2001009116A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 02/08/2001 | WO2001009115A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE |
| 02/08/2001 | WO2001009113A2 Heterocyclic compounds inhibiting angiogenesis |
| 02/08/2001 | WO2001009112A1 Novel 8-carbonyl chroman derivatives, preparation and therapeutic use thereof |
| 02/08/2001 | WO2001009103A2 Imidazole antiproliferative agents |
| 02/08/2001 | WO2001009090A2 Hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines |
| 02/08/2001 | WO2001008709A1 Sonoporation of tumors |
| 02/08/2001 | WO2001008708A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 02/08/2001 | WO2001008707A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 02/08/2001 | WO2001008704A2 Dendrimer-photosensitizer complexes for medical applications |
| 02/08/2001 | WO2001008698A1 Activity potentiators for chemotherapeutics, anticancer compositions and method for potentiating the activity of chemotherapeutics |
| 02/08/2001 | WO2001008693A2 Combination therapy using pentafluorobenzenesulfonamide and platin compound |
| 02/08/2001 | WO2001008691A1 Methods for transdifferentiation of body tissues |
| 02/08/2001 | WO2001008684A1 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 02/08/2001 | WO2001008663A2 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 02/08/2001 | WO2001008636A2 Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| 02/08/2001 | WO2001008634A2 Polynucleotide encoding a human serine protease |
| 02/08/2001 | WO2000075317A3 Compositions and methods for the treatment of tumor |
| 02/08/2001 | WO2000069894A3 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
| 02/08/2001 | WO2000069520A3 Use of topical azathioprine to treat inflammatory bowel disorders |
| 02/08/2001 | WO2000069456A3 Adjuvant combination formulations |
| 02/08/2001 | WO2000067769A8 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents |
| 02/08/2001 | WO2000066724A3 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna |
| 02/08/2001 | WO2000066590A3 Tetracyclic progesterone receptor modulator compounds and methods |
| 02/08/2001 | WO2000066528A3 Quinones for treatment of diseases |
| 02/08/2001 | WO2000063406A3 Adenoviral vectors having nucleic acids encoding immunomodulatory molecules |
| 02/08/2001 | WO2000063247A3 Osteopontin-derived chemotactic and inhibitory agents and uses therefor |
| 02/08/2001 | WO2000063230A3 49 human secreted proteins |
| 02/08/2001 | WO2000061772A3 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| 02/08/2001 | WO2000061756A3 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| 02/08/2001 | WO2000061183A3 Verotoxin treatment of lymphomas |
| 02/08/2001 | WO2000056737A3 Calanolides for inhibiting btk |
| 02/08/2001 | DE19937394A1 Fluorenderivate Fluoro derivatives |
| 02/08/2001 | DE19936563A1 Tumorassoziiertes Antigen Tumor-associated antigen |
| 02/08/2001 | DE19935303A1 Oligonukleotide zur Inhibierung der Expression von humanem eg5 Oligonucleotides for inhibiting the expression of human Eg5 |
| 02/08/2001 | DE19935302A1 Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen Conjugates and methods for their preparation and their use for transporting molecules across biological membranes |
| 02/08/2001 | CA2697207A1 Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications |
| 02/08/2001 | CA2393917A1 Bisplatinum complexes active through the oral route |
| 02/08/2001 | CA2393915A1 1,2-dihydro-1-oxo-pyrazino¬1,2-a|indole derivatives |
| 02/08/2001 | CA2391348A1 Enhanced delivery via serpin enzyme complex receptor |
| 02/08/2001 | CA2381945A1 Mammalian adhesion protease peptides |
| 02/08/2001 | CA2381565A1 Therapeutic compounds comprised of anti-fc receptor binding agents |
| 02/08/2001 | CA2381056A1 Recombinant hsv-1 and live viral vaccines |
| 02/08/2001 | CA2381004A1 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins |
| 02/08/2001 | CA2380837A1 High affinity tgf.beta. nucleic acid ligands and inhibitors |
| 02/08/2001 | CA2380813A1 Human monoclonal antibodies to her2/neu |
| 02/08/2001 | CA2380644A1 2-pyrazolin-5-ones |
| 02/08/2001 | CA2380631A1 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| 02/08/2001 | CA2380582A1 New cytotoxic pyrido[2,3,4-kl]acridine derivatives, their preparation and their therapeutic use |
| 02/08/2001 | CA2380578A1 Ring opened cpis |
| 02/08/2001 | CA2380489A1 Modulating binding site on potassium channels used for screening |
| 02/08/2001 | CA2380473A1 Tenascin-c nucleic acid ligands |
| 02/08/2001 | CA2380428A1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app) |
| 02/08/2001 | CA2380379A1 A method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 02/08/2001 | CA2380371A1 Thiourea and isothiourea derivatives for inhibiting ras-transformed cell growth |
| 02/08/2001 | CA2379660A1 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 02/08/2001 | CA2379360A1 Human g-protein coupled receptor |
| 02/08/2001 | CA2378942A1 Imidazole antiproliferative agents |
| 02/08/2001 | CA2378929A1 Serine proteases |
| 02/08/2001 | CA2378182A1 Compositions and methods for the treatment of tumors |
| 02/08/2001 | CA2378176A1 Heterocyclic compounds inhibiting angiogenesis |
| 02/08/2001 | CA2378140A1 Methods for transdifferentiation of body tissues |
| 02/08/2001 | CA2374743A1 Human chaperone proteins |
| 02/07/2001 | EP1074618A2 Cadherin materials and methods |
| 02/07/2001 | EP1074560A2 Crude extract from viscum album coloratum, and proteins and lectins isolated therefrom |
| 02/07/2001 | EP1074542A1 Sulfonamide-containing indole compounds |
| 02/07/2001 | EP1074257A1 2,7-Substituted octahydro-1H-pyrido (1,2-A)pyrazine derivatives as ligands for serotonin receptors |
| 02/07/2001 | EP1074248A1 Delivery system for biological material |
| 02/07/2001 | EP1073758A1 Retroviral vectors including modified envelope escort proteins |
| 02/07/2001 | EP1073749A2 Enhancing immune responses to genetic immunization by using a chemokine |
| 02/07/2001 | EP1073742A2 Human nucleic acid sequences of bladder tumour tissue |
| 02/07/2001 | EP1073740A1 Polynucleotides isolated from skin cells and methods for their use |
| 02/07/2001 | EP1073739A2 Cd40-interacting and traf-interacting proteins |
| 02/07/2001 | EP1073738A2 Human k+ ion channel and therapeutic applications thereof |
| 02/07/2001 | EP1073736A1 Delayed rectifier potassium channel subunit |
| 02/07/2001 | EP1073734A2 Tumor associated nucleic acids and uses therefor |
| 02/07/2001 | EP1073733A1 MUTATED PEPTIDE COMPOUNDS, DERIVED FROM hsp70, USEFUL IN CANCER IMMUNOTHERAPY |
| 02/07/2001 | EP1073729A2 Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth |
| 02/07/2001 | EP1073728A2 Insulin-like growth factor ii antisense oligonucleotide sequences and methods of using same to modulate cell growth |
| 02/07/2001 | EP1073727A2 Human nucleic acid sequences from ovarian tumour tissue |
| 02/07/2001 | EP1073723A2 Ste20-related protein kinases |
| 02/07/2001 | EP1073682A1 Heparanase specific molecular probes and their use in research and medical applications |
| 02/07/2001 | EP1073681A1 Cloning of a novel 7tm receptor axor-2 |
| 02/07/2001 | EP1073667A2 Polysaccharide-antigen conjugates |
| 02/07/2001 | EP1073658A1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
| 02/07/2001 | EP1073654A1 2,3-olefinic epothilone derivatives |
| 02/07/2001 | EP1073648A1 12,13-Modified epothilone derivatives |
| 02/07/2001 | EP1073647A1 12,13-cyclopropane epothilone derivatives |
| 02/07/2001 | EP1073641A2 New substituted amides, their production and their use |
| 02/07/2001 | EP1073635A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| 02/07/2001 | EP1073633A2 Substituted beta-amino acid inhibitors of methionine aminopeptidase-2 |
| 02/07/2001 | EP1073632A1 Substituted benzamides, their production and their use as cysteine protease inhibitors |
| 02/07/2001 | EP1073469A1 Stable mitoxantron solutions |
| 02/07/2001 | EP1073465A1 T cell inhibitory receptor compositions and uses thereof |
| 02/07/2001 | EP1073435A1 Substituted tricyclic pyrazole derivatives with protein kinase activity |
| 02/07/2001 | EP1043318A4 Salts of 5,5'-arylidenebisbarbituric and 5,5'-arylidenebis(2-thiobarbituric) acids and 5,5'-arylidenebis(2-thiobarbituric) acids having an antibacterial, anti-chlamydial, antiviral and immuno-modulating activity |
| 02/07/2001 | CN1283234A Method for suppressing multiple drug resistant in cancer cells |
| 02/07/2001 | CN1283192A Inhibition of raf kinase using aryl and hetroaryl substituted heterocyclic ureas |
| 02/07/2001 | CN1283183A Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |